Patents by Inventor Carsten Fischer

Carsten Fischer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10576088
    Abstract: It was found that finafloxacin has a high solubility in the presence of Tris. Such solubility is significantly higher than in the presence of other compounds typically used as buffers (e.g. phosphate buffer). The observed significant increase in solubility of finafloxacin in compositions comprising Tris is further advantageously accompanied by a long term stability of such solutions. Tris is therefore to be regarded as a specific tool to considerably enhance the solubility of finafloxacin in solutions. By preparing compositions comprising Tris it is possible to dissolve finafloxacin in such an amount therein that these compositions can effectively be used as parenteral compositions for the treatment of bacterial infections.
    Type: Grant
    Filed: October 9, 2015
    Date of Patent: March 3, 2020
    Assignee: MerLion Pharmaceuticals Pte. Ltd.
    Inventors: Carsten Fischer, Andreas Vente, Sven-Eric Wohlert
  • Patent number: 10485805
    Abstract: It was found that finafloxacin eradicates pathogens from patients suffering from bacterial infections like urinary tract infections and pyelonephritis more quickly than other fluoroquinolones regularly used for the treatment of these patients. Due to the efficacy of finafloxacin reduced treatment durations without increasing the daily dosage of finafloxacin and at the same time no or shorter stays in hospital are realizable, thus improving patient convenience and significantly lowering the costs of hospitalization and treatment. Reduced hospitalization periods do also clearly reduce the risk of nosocomial infections and of generating drug-resistant strains through extended therapy. The inventive treatment regimens comprise an oral finafloxacin administration for 1-5 days or a parenteral finafloxacin administration for 1-5 days for use in the treatment of a complicated urinary tract infection or pyelonephritis. However, a prior short parenteral administration of finafloxacin (e.g.
    Type: Grant
    Filed: November 10, 2015
    Date of Patent: November 26, 2019
    Assignee: MerLion Pharmaceuticals Pte. Ltd.
    Inventors: Christine Bentley, Carsten Fischer, Mark Lückermann, Andreas Vente, Sven-Eric Wohlert
  • Publication number: 20170354661
    Abstract: It was found that finafloxacin eradicates pathogens from patients suffering from bacterial infections like urinary tract infections and pyelonephritis more quickly than other fluoroquinolones regularly used for the treatment of these patients. Due to the efficacy of finafloxacin reduced treatment durations without increasing the daily dosage of finafloxacin and at the same time no or shorter stays in hospital are realizable, thus improving patient convenience and significantly lowering the costs of hospitalization and treatment. Reduced hospitalization periods do also clearly reduce the risk of nosocomial infections and of generating drug-resistant strains through extended therapy. The inventive treatment regimens comprise an oral finafloxacin administration for 1-5 days or a parenteral finafloxacin administration for 1-5 days for use in the treatment of a complicated urinary tract infection or pyelonephritis. However, a prior short parenteral administration of finafloxacin (e.g.
    Type: Application
    Filed: November 10, 2015
    Publication date: December 14, 2017
    Inventors: Christine Bentley, Carsten Fischer, Mark Lückermann, Andreas Vente, Sven-Eric Wohlert
  • Publication number: 20170326151
    Abstract: It was found that finafloxacin has a high solubility in the presence of Tris. Such solubility is significantly higher than in the presence of other compounds typically used as buffers (e.g. phosphate buffer). The observed significant increase in solubility of finafloxacin in compositions comprising Tris is further advantageously accompanied by a long term stability of such solutions. Tris is therefore to be regarded as a specific tool to considerably enhance the solubility of finafloxacin in solutions. By preparing compositions comprising Tris it is possible to dissolve finafloxacin in such an amount therein that these compositions can effectively be used as parenteral compositions for the treatment of bacterial infections.
    Type: Application
    Filed: October 9, 2015
    Publication date: November 16, 2017
    Applicant: MerLion Pharmaceuticals Pte. Ltd.
    Inventors: Carsten Fischer, Andreas Vente, Sven-Eric Wohlert
  • Patent number: 8013070
    Abstract: Novel crosslinkable compositions are provided and are based on thermoplastic polymers and elastomers, these compositions comprising, as crosslinking system, specific organic salts of metal ions. Ionically crosslinked thermoplastic elastomers can be obtained therefrom and have excellent physical properties, high-temperature resistance extending above 150° C., and also oil resistance. They can be used for production of moldings.
    Type: Grant
    Filed: September 1, 2006
    Date of Patent: September 6, 2011
    Assignee: LANXESS Deutschland GmbH
    Inventors: Dirk Achten, Claus Wrana, Kay Varnhorn, Stephen Pask, Carsten Fischer
  • Patent number: 7799904
    Abstract: A nucleic acid molecule encoding the gilvocarcin V gene cluster and subunits thereof. Recombinant vectors and host cells comprising a nucleic acid compound encoding the gilvocarcin V gene cluster or subunits thereof. Host cells comprising recombinant vectors encoding the gilvocarcin polyketide synthase and gilvocarcin post-PKS modifying enzymes from Streptomyces griseoflavus can be used to produce gilvocarcin and functional gilvocarcin mutants, analogs and derivatives thereof with application as antibiotics, anticancer agents, immunosuppressants, antivirals, and neuroprotective agents.
    Type: Grant
    Filed: June 14, 2004
    Date of Patent: September 21, 2010
    Assignee: University of Kentucky Research Foundation
    Inventors: Jurgen Rohr, Carsten Fischer
  • Publication number: 20070055018
    Abstract: Novel crosslinkable compositions are provided and are based on thermoplastic polymers and elastomers, these compositions comprising, as crosslinking system, specific organic salts of metal ions. Ionically crosslinked thermoplastic elastomers can be obtained therefrom and have excellent physical properties, high-temperature resistance extending above 150° C., and also oil resistance. They can be used for production of mouldings.
    Type: Application
    Filed: September 1, 2006
    Publication date: March 8, 2007
    Inventors: Dirk Achten, Claus Wrana, Kay Varnhorn, Stephen Pask, Carsten Fischer
  • Publication number: 20050048536
    Abstract: A nucleic acid molecule encoding the gilvocarcin V gene cluster and subunits thereof. Recombinant vectors and host cells comprising a nucleic acid compound encoding the gilvocarcin V gene cluster or subunits thereof. Host cells comprising recombinant vectors encoding the gilvocarcin polyketide synthase and gilvocarcin post-PKS modifying enzymes from Streptomyces griseoflavus can be used to produce gilvocarcin and functional gilvocarcin mutants, analogs and derivatives thereof with application as antibiotics, anticancer agents, immunosuppressants, antivirals, and neuroprotective agents.
    Type: Application
    Filed: June 14, 2004
    Publication date: March 3, 2005
    Inventors: Jurgen Rohr, Carsten Fischer
  • Patent number: D874706
    Type: Grant
    Filed: November 9, 2017
    Date of Patent: February 4, 2020
    Inventor: Carsten Fischer